Danimer Scientific, Inc. provided earnings guidance for the year 2022. The Company expects full year 2022 will be another year of investment, with an intense focus on getting its PHA-based business to profitability. The Company expects its Kentucky facility to have a favorable year-over-year impact and to turn profitable as it increases its PHA-based revenues and drives operational efficiencies.

The improved profitability from PHA-based revenues is expected to be more than offset by lower PLA-based revenue, a full year of prior SG&A and R&D investments to support growth, as well as a full year of consolidated costs from Danimer Catalytic Technologies acquired in August 2021. Looking beyond 2022, the Company expects its PHA-based revenues to drive a significant increase in the Company's overall profitability. The Company remains confident in its ability to execute against its objectives with a prudent focus on profitability and cash management.